TMS denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Limits TMS Quantity — and How to Appeal

Aetna's coverage policy for transcranial magnetic stimulation (TMS) specifies limits on the number of TMS sessions covered within a treatment course or plan year. These limits reflect the session parameters studied in the evidence base Aetna relied upon when writing its policy — they are not a clinical determination about your individual response or ongoing need. When your treating clinician determines that you need additional sessions beyond those limits, a quantity-limit exception appeal is the appropriate path.

## Why This Denial Is Appealable

Quantity-limit appeals for TMS succeed when the record demonstrates that: (a) the standard session allotment produced a partial but incomplete response and continued treatment is expected to yield further benefit, (b) your clinical presentation requires a longer course than the policy anticipates, or (c) you are in a maintenance or re-treatment phase for which the relevant specialty guidelines (e.g., from the applicable American Psychiatric Association or similar body) recognize ongoing TMS as appropriate. The key is individualized clinical documentation — not arguments about population-level data.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. Aetna must decide within 30 days for pre-service and 60 days for post-service requests.
• External review (ACA §2719 / ERISA §503): After internal denial, request independent external review within approximately four months of the final adverse determination. External reviewers frequently overturn quantity-limit denials when individualized clinical need is well-documented.
• Mental Health Parity (MHPAEA): Confirm that any session limits applied to TMS are no more restrictive than limits applied to comparable medical/surgical neuromodulation procedures — a parity violation provides an independent appeal ground.
• Expedited review: Available if standard timelines would endanger health.

## Documentation to Gather

1. Treatment progress records: Session-by-session clinical notes documenting symptom trajectory, validated scale scores at baseline and at the point of the limit, and the treating clinician's assessment of remaining therapeutic potential. 2. Prescriber justification letter: A letter from your TMS provider and/or psychiatrist explaining why additional sessions are medically necessary, what clinical response has been achieved so far, and what further benefit is anticipated — with reference to the applicable guideline organization. 3. Diagnosis and severity confirmation: Current records confirming diagnosis and functional impairment status. 4. Prior-treatment context: Documentation of why TMS was initiated and the treatment history before TMS, to contextualize the importance of completing an adequate course. 5. Parity comparator (if applicable): If you or your clinician can identify a comparable medical procedure for which Aetna does not apply analogous quantity limits, note this in the appeal.

## Criteria-Mapping Structure

Obtain Aetna's Clinical Policy Bulletin for TMS from Aetna.com and identify the specific quantity parameters and any exception language. Map each exception criterion to chart evidence: (1) Aetna Criterion, (2) Chart Evidence, (3) Document/Date. The progress-documentation exhibit is the centerpiece — show the reviewer a clear clinical trajectory that makes additional sessions medically reasonable, not merely convenient.